Helping Ease Renal Failure with Shenbing Decoction III Trial: A Randomised Controlled Trial of Shenbing decoction III for Slowing Kidney Failure Progression in Stage 3-5 Chronic Kidney Disease in Non-Dialysis Patients.

Southern Medical University Sinowest Medical Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Meet the 2012 KDIGO Chronic Kidney Disease Clinical Practice Guidelines CKD 3-5 diagnostic criteria;
•2. The TCM syndrome type conforms to the syndrome differentiation standard of spleen-kidney qi deficiency, turbid toxin and blood stasis;
•3. Age 18-70 years old (including 18 years old and 70 years old);
•4. Infection, acidosis, electrolyte imbalance, hypertension, etc. are effectively controlled (Bp<140/90mmHg);
•5. If ACEI/ARB drugs are used, stable dose treatment is required for more than 2 weeks (inclusive);
•6. No treatment with traditional Chinese medicine or proprietary Chinese medicine within 1 month before participating in the clinical trial;
•7. The lead-in period is 4 weeks. At the beginning of the lead-in period and the end of the lead-in period, the patients must undergo the following tests respectively. Only those who meet the standards for both test results can enter the test: eGFR<60mL/(min/1.73m2), Bp<140 /90mmHg;
•8. The subjects voluntarily signed the informed consent.

•1. Coronary heart disease, myocardial infarction, severe arrhythmia, malignant tumor, serious complications such as liver, kidney, hematopoietic system, and severe mental disorders;
•2. Acute and chronic nephritis, acute kidney injury, recent history of using nephrotoxic drugs;
•3. Patients with renal replacement therapy such as hemodialysis, peritoneal dialysis, and kidney transplantation;
•4. Women who are pregnant, planning to become pregnant or breastfeeding;
•5. Those who are allergic to the test drug;
•6. Those who are participating in clinical trials of other drugs or have participated in other clinical trials within 3 months;
•7. The researchers believe that other reasons are not suitable to participate in the clinical trial.

发起方

Southern Medical University Sinowest Medical Hospital